P. Gómez

发表

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Anton Belousov, Wolfgang Eiermann, M. Cheang, 2014, Clinical Cancer Research.

RESILIENCE: Phase III Randomized, Double‐Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2‐Negative Breast Cancer

J. Bergh, C. Hudis, W. Gradishar, 2017, Clinical breast cancer.

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

M. Espié, J. Baselga, P. Hoff, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.

M. Lacouture, P. Gómez, 2011, The oncologist.

CARDIAC MONITORING IN HER-2 POSITIVE ELDERLY PATIENTS TREATED WITH TRANSTUZUMAB

C., J., J. Cortés, 2014 .

Targeted therapy in advanced colon cancer: the role of new therapies.

J. Baselga, R. Salazar, J. Tabernero, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases

J. Reis-Filho, B. Weigelt, P. Nuciforo, 2018, Oncotarget.

Clinical Presentation and Management of Hand–Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Experience in Breast Cancer selected in patients with and considers

P. Gómez, 2011 .

Feasibility of pegfilgrastim as haematopoietic support for dose-dense every-2-week adjuvant chemotherapy in breast cancer.

J. Baselga, E. Vilar, J. Cortés, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE)

J. Bergh, C. Hudis, W. Gradishar, 2014 .

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

R. Greil, A. Schneeweiss, J. Baselga, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

C. Caldas, J. Baselga, S. Cairo, 2018, EMBO molecular medicine.

Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).

J. Baselga, J. Mayordomo, A. Lluch, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Unveiling changes in the landscape of patient populations in cancer early drug development

J. Carles, P. Gómez, C. Hierro, 2016, Oncotarget.

3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)

J. Baselga, A. Lluch, A. Giglio, 2009 .

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor

K. Blackwell, H. Burris, S. Isakoff, 2015, Breast Cancer Research and Treatment.

Management of the axilla in early breast cancer patients in the genomic era.

S. Di Cosimo, I. Rubio, J. Balmaña, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

M. Piccart, E. Rutgers, S. Litière, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project

V. Torri, X. Pivot, G. Bocci, 2019, Advances in Therapy.

SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).

J. Baselga, E. Ciruelos, P. Gómez, 2009 .

Progress against solid tumors in danger: the metastatic breast cancer example.

E. Perez, G. Hortobagyi, H. Rugo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Baselga, J. Tabernero, S. Cosimo, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort

H. Fiegl, Chetana Basavaraj, V. Peg, 2022, Breast.

Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis.

À. Rovira, D. Torrejon, S. Di Cosimo, 2013, Breast.

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

Paolo Morandi, Ana Lluch, Patricia Gomez, 2012, Breast Cancer Research and Treatment.

Abstract P2-01-06: Association between Circulating Tumor Cells and Bone Turnover Markers in patients with breast cancer and bone metastases on treatment with bisphosphonates (ZOMAR study)

I. Tusquets, M. Margelí, L. Calvo, 2012 .

4005 Trastuzumab-related cardiotoxicity in the elderly: which role for cardiovascular risk factors?

J. Baselga, S. Cosimo, C. Serrano, 2009 .

Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).

P. Nuciforo, R. Dienstmann, E. Zamora, 2019, Journal of Clinical Oncology.

Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).

M. Margelí, A. de Juan, L. Calvo, 2014, Bone.

A phase II study of pazopanib (GW786034) in patients with stage IV non-small cell lung cancer that have failed at least two prior chemotherapy regimens.

J. Wade, P. Gómez, J. Harper, 2014 .